Liquidia Corporation

We are deeply passionate and committed to the discovery, engineering, and development required to bring novel therapies to patients who need them most, and to the healthcare providers who care for them. Our current drive is toward improving the treatment of pulmonary arterial hypertension (PAH).

We will continue to combine our proprietary, innovative PRINT Technology with new and established medications, offering the potential for both better precision and improved clinical outcomes.

News Releases

APR 02 2024

Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference

MORRISVILLE, N.C. , April 02, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) ( Liquidia or the Company) announced today that Dr. Roger Jeffs , Chief Executive Officer, and Micheal Kaseta , Chief Operating Officer and Chief Financial Officer, will provide an overview and update on the
APR 01 2024

Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder

On March 28 , Judge Andrews removed the injunction issued in the Original Hatch Waxman Litigation On March 29 , Judge Bates denied United Therapeutics’ motion for temporary restraining order and preliminary injunction in separate litigation filed by United Therapeutics against the FDA On March 31 ,

btn News